Trevi Therapeutics (TRVI) Change in Acquisitions & Divestments (2022 - 2026)

Trevi Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $25.6 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 45.22% year-over-year to $25.6 million; the TTM figure through Mar 2026 stood at $84.5 million (up 16.76% YoY), while the FY2025 annual figure was $76.6 million, down 0.52% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $25.6 million, up from $23.8 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $25.6 million in Q1 2026, with the low at $12.8 million in Q2 2024.
• The 5-year median for Change in Acquisitions & Divestments is $18.8 million (2023), against an average of $19.0 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 54.34% in 2024, while the deepest fall reached 35.19% in 2024.
• Trevi Therapeutics' Change in Acquisitions & Divestments stood at $17.0 million in 2022, then fell by 18.72% to $13.8 million in 2023, then soared by 54.34% to $21.3 million in 2024, then advanced by 11.54% to $23.8 million in 2025, then gained by 7.42% to $25.6 million in 2026.
• Business Quant data shows TRVI's Change in Acquisitions & Divestments at $25.6 million in Q1 2026, $23.8 million in Q4 2025, and $20.7 million in Q3 2025.